Volume 27, Number 3—March 2021
Synopsis
Decentralized Care for Rifampin-Resistant Tuberculosis, Western Cape, South Africa
Table 3
Linear temporal trends in magnitude and duration of movement for adult patients with RR TB, Western Cape, South Africa, 2012–2014*
Description | Overall, n = 2,878 |
Cape Town, n = 1,878 |
Outside Cape Town, n = 1,000 |
Interaction p value† | |||||
---|---|---|---|---|---|---|---|---|---|
Slope (95% CI) | p value | Slope (95% CI) | p value | Slope (95% CI) | p value | ||||
Hospitalization in TB hospital, no. (%)
No. patients with >1 sample from a specialized TB hospital in the first year after RR TB diagnosis |
−0.4
(−1.2 to 0.5) |
0.33 |
−1.0
(−1.7 to −0.2) |
0.02 |
1.1
(−0.9 to 3.1) |
0.23 |
0.03 |
||
Moved to care outside TB hospital, no. (%)
No. patients with a sample from a TB hospital who had a subsequent sample from a non-TB hospital <3 mo after the most recent sample in the TB hospital |
0.2
(−0.9 to 1.3) |
0.69 |
0.1
(−1.3 to 1.6) |
0.84 |
−0.01
(−1.8 to 1.8) |
0.99 |
0.89 |
||
Median length of TB hospital stay, d (IQR)
Median hospitalization period of patients who moved to care outside of a TB hospital in the first year after RR TB diagnosis |
−1.5
(−5.7 to 2.6) |
0.42 |
−3.6 (−8.7 to 1.5) |
0.14 |
−0.28
(−4.3 to 3.7) |
0.87 |
0.24 |
||
Any movement, no. (%)
No. patients who had samples from >2 different facilities in first year after RR TB diagnosis |
−0.5
(−1.2 to 0.3) |
0.19 |
−0.9
(−1.7 to −0.06) |
0.04 |
0.5
(−1.2 to 2.3) |
0.50 |
0.10 |
||
Median no. of visits (IQR)
No. unique days with >1 laboratory sample in the first year after RR TB diagnosis |
0.04
(−0.01 to 0.1) |
0.12 |
0.0
(−0.2 to 0.2) |
>0.99 |
0.1
(−0.01 to 0.2) |
0.06 |
0.22 |
||
Median total distance, km (IQR)
Total Euclidian distance between all facilities visited by each patient in the first year after RR TB diagnosis |
−0.1
(−0.4 to 0.2) |
0.43 |
−0.3
(−0.5 to −0.01) |
0.04 |
4.7
(−1.3 to 10.6) |
0.10 |
0.07 |
||
Median distance between consecutive visits, km (IQR) Median distance between facilities visited consecutively by each patient in the first year after RR TB diagnosis | −0.06 (−0.2 to 0.04) | 0.21 | −0.18 (−0.4 to −0.02) | 0.07 | 2.5 (−0.5 to 5.6) | 0.09 | 0.05 |
*Patients without second-line drug resistance who attended >2 visits. Estimates are change per quarter (i.e., 3 mos). RR, rifampin-resistant; TB, tuberculosis. †p value of interaction term between quarter of diagnosis and location.
Page created: January 29, 2021
Page updated: February 21, 2021
Page reviewed: February 21, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.